Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Medicinova Inc (NQ: MNOV ) 1.900 +0.210 (+12.43%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 129,167 Open 1.740 Bid (Size) 1.820 (2) Ask (Size) 1.950 (7) Prev. Close 1.690 Today's Range 1.740 - 2.000 52wk Range 1.120 - 2.380 Shares Outstanding 49,046,246 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND September 09, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting September 03, 2024 From MediciNova, Inc. Via GlobeNewswire Performance YTD +15.15% +15.15% 1 Month +53.23% +53.23% 3 Month +48.44% +48.44% 6 Month +33.80% +33.80% 1 Year -9.09% -9.09% More News Read More MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition August 29, 2024 From MediciNova, Inc. Via GlobeNewswire Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024 August 19, 2024 Via InvestorPlace MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations June 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer June 05, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 June 03, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions May 28, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer May 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome May 14, 2024 From MediciNova, Inc. Via GlobeNewswire MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024 May 10, 2024 Via InvestorPlace MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) May 07, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session April 05, 2024 Via Benzinga MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) April 02, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 27, 2024 Via Benzinga Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket March 27, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday March 27, 2024 Via InvestorPlace MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan March 26, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society March 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology March 12, 2024 From MediciNova, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 27, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session February 16, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 13, 2024 Via Benzinga MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China January 17, 2024 From MediciNova, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
